Advanced search
Publication Cover
Journal of Asthma Volume 49, 2012 - Issue 6
Submit an article Journal homepage
993
Views
22
CrossRef citations to date
0
Altmetric
Pharmacotherapy

Longitudinal Changes in Asthma Control with Omalizumab: 2-Year Interim Data from the EXCELS Study

Mark D. EisnerProduct Development, Inflammation & Respiratory, Genentech, Inc., South San Francisco, CA, USACorrespondence[email protected]
, M.D., M.Ph.,
James L. ZazzaliProduct Development, Inflammation & Respiratory, Genentech, Inc., South San Francisco, CA, USA
, Ph.D., M.Ph.,
Mary K. MillerProduct Development, Inflammation & Respiratory, Genentech, Inc., South San Francisco, CA, USA
, M.S.,
Mary S. BradleyProduct Development, Inflammation & Respiratory, Genentech, Inc., South San Francisco, CA, USA
, M.S. &
Michael SchatzDepartment of Allergy, Kaiser Permanente Medical Center, San Diego, CA, USA
, M.D., M.S.
Pages 642-648 | Published online: 16 Jul 2012

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Robert M. Niven, Michael R. Simmonds, Michael J. Cangelosi, Dominic P. Tilden, Suzanne Cottrell & Narinder S. Shargill. (2018) Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma. Journal of Asthma 55:4, pages 443-451.
Read now
Arzu Didem Yalcin, Aykut Cilli, Atil Bisgin, Ludwig G Strauss & Felix Herth. (2013) Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels. Expert Opinion on Biological Therapy 13:9, pages 1335-1341.
Read now
Neil Barnes, Andrew Menzies-Gow, Adel H. Mansur, David Spencer, Fran Percival, Amr Radwan & Rob Niven. (2013) Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study. Journal of Asthma 50:5, pages 529-536.
Read now
Priyanka Vashisht & Thomas Casale. (2013) Omalizumab for treatment of allergic rhinitis. Expert Opinion on Biological Therapy 13:6, pages 933-945.
Read now

Articles from other publishers (18)

V. V. Naumova, E. K. Beltyukov, D. V. Kiseleva, A. A. Shtanova & D. A. Stepina. (2023) Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract. Meditsinskiy sovet = Medical Council:20, pages 68-83.
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
Nikolaos G. Papadopoulos, Peter Barnes, Giorgio Walter Canonica, Mina Gaga, Liam Heaney, Andrew Menzies‐Gow, Vicky Kritikos & Mark Fitzgerald. (2020) The evolving algorithm of biological selection in severe asthma. Allergy 75:7, pages 1555-1563.
Crossref
Fozia Masood. 2020. Sino-Nasal Disorders [Working Title]. Sino-Nasal Disorders [Working Title].
Ravdeep Kaur & Geoffrey Chupp. (2019) Phenotypes and endotypes of adult asthma: Moving toward precision medicine. Journal of Allergy and Clinical Immunology 144:1, pages 1-12.
Crossref
Paraskevi Katsaounou, Roland Buhl, Guy Brusselle, Pascal Pfister, Rafael Martínez, Ulrich Wahn & Jean Bousquet. (2019) Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory Medicine 150, pages 51-62.
Crossref
Carlos Iribarren, Abdelkader Rahmaoui, Aidan A. Long, Stanley J. Szefler, Mary S. Bradley, Gillis Carrigan, Mark D. Eisner, Hubert Chen, Theodore A. Omachi, Michael E. Farkouh & Kenneth J. Rothman. (2017) Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. Journal of Allergy and Clinical Immunology 139:5, pages 1489-1495.e5.
Crossref
M. Caminati, G. Senna, G. Stefanizzi, R. Bellamoli, S. Longhi, F. Chieco-Bianchi, G. Guarnieri, S. Tognella, M. Olivieri, C. Micheletto, G. Festi, E. Bertocco, M. Mazza, A. Rossi & A. Vianello. (2016) Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulmonary Medicine 16:1.
Crossref
Brian R. Wingrove. (2016) An Overview of Pediatric Asthma. Physician Assistant Clinics 1:4, pages 563-582.
Crossref
María del Carmen Vennera, Antonio Valero, Estefany Uría, Carles Forné & César Picado. (2016) Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical Drug Investigation 36:7, pages 567-578.
Crossref
Alice M. Turner, Lilla Tamasi, Florence Schleich, Mehmet Hoxha, Ildiko Horvath, Renaud Louis & Neil Barnes. (2015) Clinically relevant subgroups in COPD and asthma. European Respiratory Review 24:136, pages 283-298.
Crossref
Marco Caminati, Gianenrico Senna, Massimo Guerriero, Anna Rita Dama, Fulvia Chieco-Bianchi, Giorgia Stefanizzi, Marcello Montagni & Erminia Ridolo. (2015) Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address. Pulmonary Pharmacology & Therapeutics 31, pages 28-35.
Crossref
Arzu Didem Yalcin. (2015) Advances in Anti-IgE Therapy. BioMed Research International 2015, pages 1-11.
Crossref
AD Yalcin. (2014) ANTI-Ige: An Overview. Global Journal of Allergy, pages 003-012.
Crossref
Marianne Frieri. (2014) Asthma Linked with Rhinosinusitis: An Extensive Review. Allergy & Rhinology 5:1, pages ar.2014.5.0083.
Crossref
Arzu Didem Yalcin. (2014) An Overview of the Effects of anti-IgE Therapies. Medical Science Monitor 20, pages 1691-1699.
Crossref
Matthew C. Bell & William W. Busse. (2013) Severe Asthma: An Expanding and Mounting Clinical Challenge. The Journal of Allergy and Clinical Immunology: In Practice 1:2, pages 110-121.
Crossref
Yasuo Shimizu & Kunio Dobashi. (2012) CC-Chemokine CCL15 Expression and Possible Implications for the Pathogenesis of IgE-Related Severe Asthma. Mediators of Inflammation 2012, pages 1-7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.